Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

107 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Emapalumab as salvage therapy for adults with malignancy-associated hemophagocytic lymphohistiocytosis.
Johnson WT, Epstein-Peterson ZD, Ganesan N, Pak T, Chang T, Dao P, Moskowitz AJ, Stuver RN, Ghione P, Galasso N, Khan N, Palomba ML, Caron PC, Kumar A, Tamari R, Lue JK, Noy A, Falchi L, Intlekofer AM, Gyurkocza B, Perales MA, Scordo M, Herskovits AZ, Salles G, Vardhana SA, Horwitz SM. Johnson WT, et al. Among authors: ganesan n. Haematologica. 2024 Sep 1;109(9):2998-3003. doi: 10.3324/haematol.2023.284179. Haematologica. 2024. PMID: 38752279 Free PMC article. No abstract available.
Risk of breast implant associated anaplastic large cell lymphoma (BIA-ALCL) in a cohort of 3546 women prospectively followed long term after reconstruction with textured breast implants.
Cordeiro PG, Ghione P, Ni A, Hu Q, Ganesan N, Galasso N, Dogan A, Horwitz SM. Cordeiro PG, et al. Among authors: ganesan n. J Plast Reconstr Aesthet Surg. 2020 May;73(5):841-846. doi: 10.1016/j.bjps.2019.11.064. Epub 2020 Jan 20. J Plast Reconstr Aesthet Surg. 2020. PMID: 32008941 Free PMC article.
T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma.
Ghione P, Faruque P, Mehta-Shah N, Seshan V, Ozkaya N, Bhaskar S, Yeung J, Spinner MA, Lunning M, Inghirami G, Moskowitz A, Galasso N, Ganesan N, van der Weyden C, Ruan J, Prince HM, Trotman J, Advani R, Dogan A, Horwitz S. Ghione P, et al. Among authors: ganesan n. Blood Adv. 2020 Oct 13;4(19):4640-4647. doi: 10.1182/bloodadvances.2020002396. Blood Adv. 2020. PMID: 33002132 Free PMC article.
Outcomes of adult T-Cell leukemia/lymphoma with allogeneic stem cell transplantation: single-institution experience.
Epstein-Peterson ZD, Ganesan N, Barker JN, Drullinsky PR, Ghione P, Jakubowski AA, Kumar A, Moskowitz AJ, Noy A, Perales MA, Ponce DM, Schoder H, Young JW, Giralt SA, Horwitz SM, Sauter CS, Dahi PB. Epstein-Peterson ZD, et al. Among authors: ganesan n. Leuk Lymphoma. 2021 Sep;62(9):2177-2183. doi: 10.1080/10428194.2021.1897806. Epub 2021 Mar 29. Leuk Lymphoma. 2021. PMID: 33779474 Free PMC article.
Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.
Moskowitz AJ, Shah G, Schöder H, Ganesan N, Drill E, Hancock H, Davey T, Perez L, Ryu S, Sohail S, Santarosa A, Galasso N, Neuman R, Liotta B, Blouin W, Kumar A, Lahoud O, Batlevi CL, Hamlin P, Straus DJ, Rodriguez-Rivera I, Owens C, Caron P, Intlekofer AM, Hamilton A, Horwitz SM, Falchi L, Joffe E, Johnson W, Lee C, Palomba ML, Noy A, Matasar MJ, Pongas G, Salles G, Vardhana S, Sanin BW, von Keudell G, Yahalom J, Dogan A, Zelenetz AD, Moskowitz CH. Moskowitz AJ, et al. Among authors: ganesan n. J Clin Oncol. 2021 Oct 1;39(28):3109-3117. doi: 10.1200/JCO.21.01056. Epub 2021 Jun 25. J Clin Oncol. 2021. PMID: 34170745 Free PMC article. Clinical Trial.
Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts.
Mehta-Shah N, Lunning MA, Moskowitz AJ, Boruchov AM, Ruan J, Lynch P, Hamlin PA, Leonard J, Matasar MJ, Myskowski PL, Marzouk E, Nair S, Sholklapper T, Minnal V, Palomba ML, Vredenburgh J, Kumar A, Noy A, Straus DJ, Zelenetz AD, Schoder H, Rademaker J, Schaffer W, Galasso N, Ganesan N, Horwitz SM. Mehta-Shah N, et al. Among authors: ganesan n. Am J Hematol. 2021 Oct 1;96(10):1211-1222. doi: 10.1002/ajh.26288. Epub 2021 Jul 29. Am J Hematol. 2021. PMID: 34251048 Free PMC article. Clinical Trial.
A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas.
Moskowitz AJ, Ghione P, Jacobsen E, Ruan J, Schatz JH, Noor S, Myskowski P, Vardhana S, Ganesan N, Hancock H, Davey T, Perez L, Ryu S, Santarosa A, Dowd J, Obadi O, Pomerantz L, Yi N, Sohail S, Galasso N, Neuman R, Liotta B, Blouin W, Baik J, Geyer MB, Noy A, Straus D, Kumar P, Dogan A, Hollmann T, Drill E, Rademaker J, Schoder H, Inghirami G, Weinstock DM, Horwitz SM. Moskowitz AJ, et al. Among authors: ganesan n. Blood. 2021 Dec 30;138(26):2828-2837. doi: 10.1182/blood.2021013379. Blood. 2021. PMID: 34653242 Free PMC article. Clinical Trial.
TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy.
Johnson WT, Ganesan N, Epstein-Peterson ZD, Moskowitz AJ, Stuver RN, Maccaro CR, Galasso N, Chang T, Khan N, Aypar U, Lewis NE, Zelenetz AD, Palomba ML, Matasar MJ, Noy A, Hamilton AM, Hamlin P, Caron PC, Straus DJ, Intlekofer AM, Lee Batlevi C, Kumar A, Owens CN, Sauter CS, Falchi L, Lue JK, Vardhana SA, Salles G, Dogan A, Schultz ND, Arcila ME, Horwitz SM. Johnson WT, et al. Among authors: ganesan n. Blood Adv. 2023 Sep 12;7(17):5172-5186. doi: 10.1182/bloodadvances.2023009953. Blood Adv. 2023. PMID: 37078708 Free PMC article.
107 results